Xenon Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the Jefferies 2021 Virtual Healthcare Conference on June 2, 2021, at 3:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the Jefferies 2021 Virtual Healthcare Conference on June 2, 2021, at 3:00 PM ET. The event will feature a fireside chat accessible via a live webcast. This participation highlights Xenon's commitment to advancing its pipeline of innovative therapeutics for neurological disorders, particularly focusing on epilepsy. Interested investors can find more information on the company's presentations and webcasts on their investor website. Note that the schedule is subject to change.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was +0.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, May 31, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will participate in the following investor conference:
- Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 3:00 pm ET. The live webcast of the fireside chat can be accessed here.
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Maria McClean
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.